Human TARC (CCL17)
- Known as:
- Human TARC (CCL17)
- Catalog number:
- GEM-300-201P20
- Product Quantity:
- 20 ug
- Category:
- -
- Supplier:
- SeraLab
- Gene target:
- Human TARC (CCL17)
Related genes to: Human TARC (CCL17)
- Gene:
- CCL17 NIH gene
- Name:
- C-C motif chemokine ligand 17
- Previous symbol:
- SCYA17
- Synonyms:
- TARC, ABCD-2
- Chromosome:
- 16q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-10-26
- Date modifiied:
- 2016-10-05
Related products to: Human TARC (CCL17)
Related articles to: Human TARC (CCL17)
- Atopic dermatitis is a common inflammatory skin disease affecting up to 10% of adults. Whether atopic dermatitis exhibits a strong systemic inflammatory signature remains debated. We characterized peripheral whole-blood alterations in adults with moderate-to-severe atopic dermatitis undergoing treatment with dupilumab or baricitinib therapy. Blood samples were collected at weeks 0, 4, and 16. Whole-blood proteins were measured using Olink, transcriptomic profiling was performed by RNA sequencing, and torque teno virus plasma levels were quantified by qPCR. During targeted atopic dermatitis therapy with dupilumab or baricitinib, clustering of samples based on gene expression levels showed no separation by time or treatment, with only a limited number of differentially expressed genes. Proteomic changes were similarly modest; however, treatment was consistently associated with decreased CCL17/TARC levels. Teno torque virus plasma load remained stable throughout therapy, indicating preserved immunocompetence. These findings suggest that the dominant inflammatory processes in atopic dermatitis may be largely tissue-restricted, supporting the use of peripheral biomarkers for pragmatic monitoring rather than mechanistic discovery. - Source: PubMed
Publication date: 2026/09/10
Touborg TokeFrølunde Anne SofieLitman ThomasBerg RandiKoefoed-Nielsen PernilleDeleuran MetteJohansen ClausVestergaard Christian - The objective of this exploratory study was to identify the molecular characteristics that influence survival outcomes in cases of cervical adenocarcinoma, utilising data from the TCGA (The Cancer Genome Atlas) database. - Source: PubMed
Publication date: 2026/08/30
Cakir YaseminBayramoglu Zeynep - Maternal inflammation is linked to adverse maternal and fetal outcomes, but how maternal inflammation affects fetal inflammation during mid-gestation is not known. - Source: PubMed
Goin Dana ELi LinGaw Stephanie LMorello-Frosch RachelWoodruff Tracey JEick Stephanie MRobinson Joshua F - Atopic dermatitis (AD) is a chronic inflammatory disease driven by Type 2 (Th2) inflammation. Dupilumab (anti-IL-4Rα) and tralokinumab (anti-IL-13) are effective biologic therapies, but a direct comparison of their longitudinal effects on the systemic proteome is lacking. This exploratory study aimed to identify and to differentially analyze the proteomic signatures in AD patients treated with dupilumab versus tralokinumab. - Source: PubMed
Francuzik WojciechPažur KristijanWorm Margitta - Pressure ulcer (PU) typically arises as a chronic cutaneous ulcer stemming from a complex interplay of factors. However, the underlying mechanisms of this condition remain unclear. The aim of this study was to identify inflammatory biomarkers in patients with PU. In this study, PU and normal tissues were collected from 24 patients with PU. An exploratory Olink Inflammation Panel analysis was performed to identify candidate differentially expressed proteins (DEPs) between PU and normal tissue samples from 16 of the 24 patients with PU. A total of 16 candidate DEPs were identified using an unadjusted p < 0.05 threshold between the two groups. Among them, CCL17 had the largest fold change and diagnostic potential with an optimal AUC value (0.75). In addition, CCL17, ANGPT1, FASLG, and VEGFA demonstrated high clinical relevance in the patients with PU. Immunohistochemistry and western blotting using PU tissues obtained from the remaining 8 patients confirmed the decreased expression of CCL17 in PU tissues. In conclusion, CCL17 is a novel potential biomarker for PU pathogenesis and prognosis. - Source: PubMed
Publication date: 2026/09/20
Wu LinjunZhou ShihanLi ShiqinChen YangLuo YingZhang DanCai XuchaoWang ChenmingFan LeiZhu MingliZeng LonghuanZheng Yongke